Researchers from the National Cancer Centre Singapore (NCCS) discover a genetic marker that identifies patients of aggressive blood cancer likely to respond well to a novel immunotherapy treatment...
Clinical-stage cell therapy company, Tessa Therapeutics announced the results of two independent Phase 1/2 trials of autologous CD30 CAR-T cell therapy in patients with relapsed or refractory Hodgkin...
A phase I/II clinical trial by researchers at Stanford University suggests that vaccines prepared from a patient's own tumour cells may prevent the incurable blood cancer mantle cell lymphoma (MCL)...
Designation includes early interactions with the FDA to facilitate development and discuss potential for expedited review. Tessa Therapeutics, a clinical-stage cell therapy company developing...
The drug, known as Brukinsa, is a product from Beijing-based BeiGene. It received the FDA's approval in November and will probably become available to US patients by the end of the year, Wu Xiaobin,...
Sintilimab shown to have favourable activity and acceptable toxicity in Chinese patients with relapsed or refractory classical Hodgkin lymphoma. China's homegrown drug Sintilimab designed for...
